NCT02217189

Brief Summary

Although several studies have considered the relationship between infertility and semen super oxide radical scavengers levels, no study on the effects of asthenospermia treatments such as oral zinc supplementation on superoxide radical scavengers activity which are important in fertility of the individual has been reported.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
120

participants targeted

Target at P50-P75 for phase_2

Timeline
Completed

Started Jul 2011

Shorter than P25 for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

July 1, 2011

Completed
11 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2012

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2012

Completed
2.1 years until next milestone

First Submitted

Initial submission to the registry

August 6, 2014

Completed
9 days until next milestone

First Posted

Study publicly available on registry

August 15, 2014

Completed
Last Updated

February 3, 2017

Status Verified

February 1, 2017

Enrollment Period

11 months

First QC Date

August 6, 2014

Last Update Submit

February 1, 2017

Conditions

Keywords

Zinc supplementation.Oxidative stress.Superoxide radical scavengers.Asthenospermia.Oxido-sensitive index.

Outcome Measures

Primary Outcomes (1)

  • Oxido-sensitive index level in spermatozoa and seminal plasma.

    up to three months.

Secondary Outcomes (6)

  • Volume of semen.

    up to three months.

  • Xanthine oxidase activity in spermatozoa and seminal plasma.

    up to three months.

  • Catalase like activity in spermatozoa and seminal plasma.

    up to three months.

  • Superoxide dismutase activity in spermatozoa and seminal plasma.

    up to three months.

  • Progressive sperm motility percentage.

    up to three months

  • +1 more secondary outcomes

Study Arms (2)

Zinc sulfate

EXPERIMENTAL

60 subfertile (age 32.5±3.23 year) men with asthenozoospermia was treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).

Dietary Supplement: zinc sulfate

Healthy control

NO INTERVENTION

60 fertile (age 31.6±3.3 year) men, no treatment.

Interventions

zinc sulfateDIETARY_SUPPLEMENT

The subfertile group treated with zinc sulfate, every participant took two capsules of zinc sulfate per day for three months (each one 220 mg).

Zinc sulfate

Eligibility Criteria

Age26 Years - 36 Years
Sexmale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • the presence of asthenozoospermia in the semen sample.

You may not qualify if:

  • the absence of endocrinopathy, varicocele, and female factor infertility. Smokers and alcoholic men were excluded from the study because of their recognized high seminal ROS levels and decreased antioxidant levels.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Babylon University

Hillah, Babylon, 51002, Iraq

Location

Related Publications (1)

  • Hadwan MH, Almashhedy LA, Alsalman AR. Oral Zinc Supplementation Restores Superoxide Radical Scavengers to Normal Levels in Spermatozoa of Iraqi Asthenospermic Patients. Int J Vitam Nutr Res. 2015;85(3-4):165-73. doi: 10.1024/0300-9831/a000235.

MeSH Terms

Conditions

Asthenozoospermia

Interventions

Zinc Sulfate

Condition Hierarchy (Ancestors)

Infertility, MaleGenital Diseases, MaleGenital DiseasesUrogenital DiseasesInfertilityMale Urogenital Diseases

Intervention Hierarchy (Ancestors)

SulfatesSulfuric AcidsSulfur AcidsSulfur CompoundsInorganic ChemicalsZinc Compounds

Study Officials

  • Mahmoud H. Hadwan, PhD

    Babylon University/ Iraq

    PRINCIPAL INVESTIGATOR
  • Lamia A. Almashhedy, PhD

    Babylon University/ Iraq

    STUDY DIRECTOR
  • Abdulrrazaq S. Alsalman, PhD

    Babylon University/ Iraq

    STUDY CHAIR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Mahmoud Hussein Hadwan

Study Record Dates

First Submitted

August 6, 2014

First Posted

August 15, 2014

Study Start

July 1, 2011

Primary Completion

June 1, 2012

Study Completion

July 1, 2012

Last Updated

February 3, 2017

Record last verified: 2017-02

Locations